Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma

2007 ◽  
Vol 46 (8) ◽  
pp. 761-775 ◽  
Author(s):  
Rahul A. Parikh ◽  
Jason S. White ◽  
Xin Huang ◽  
David W. Schoppy ◽  
Bora E. Baysal ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Dna Repair ◽  
Ionizing Radiation ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Repair Deficiency ◽  
Dna Repair Deficiency

Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

2013 ◽  
Vol 109 (2) ◽  
pp. 286-292 ◽  
Author(s):  
Simon Laban ◽  
Leonhard Steinmeister ◽  
Lisa Gleißner ◽  
Tobias J. Grob ◽  
Reidar Grénman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Ionizing Radiation ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Carcinoma Cells ◽  
Neck Squamous Cell Carcinoma

scholarly journals Effect of Ionizing Radiation on the Physical Biology of Head and Neck Squamous Cell Carcinoma Cells

2015 ◽  
Vol 8 (3) ◽  
pp. 517-525 ◽  
Author(s):  
Sandra M. Baker-Groberg ◽  
Sophia Bornstein ◽  
Jevgenia Zilberman-Rudenko ◽  
Mark Schmidt ◽  
Garth W. Tormoen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Ionizing Radiation ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Carcinoma Cells ◽  
Neck Squamous Cell Carcinoma

Phase ιι (window) preoperative study of olaparib with cisplatin or with durvalumab or alone or no treatment in patients with histologically proven head and neck squamous cell carcinoma who are candidates for surgery (OPHELIA).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS6096-TPS6096
Author(s):  
Amanda Psyrri ◽  
George Papaxoinis ◽  
Panagiota Economopoulou ◽  
Ioannis Kotsantis ◽  
Vassiliki Kotoula ◽  
...  
Keyword(s):  
Dna Damage ◽  
Squamous Cell Carcinoma ◽  
Dna Repair ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Cells ◽  
Squamous Cell ◽  
Response Rate ◽  
Neck Squamous Cell Carcinoma ◽  
600Mg Daily

TPS6096 Background: Novel agents are often investigated in unselected end-stage cancer patients and their efficacy is evaluated by the classical RECIST criteria making unlikely to fully exploit the antitumor potential of these targeted agents. Olaparib (O) is a potent inhibitor of PARP especially active in tumors that have homologous recombination DNA repair pathway deficiencies. Durvalumab (D) is a selective, high-affinity human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, overcoming PD-L1-mediated inhibition of T-cell activation. There is substantial evidence that tumor cells use PARP to repair platinum-induced DNA damage and thus escape apoptosis. In addition, O may complement the antitumor activity of D by increasing DNA damage through repair inhibition. Methods: OPHELIA is an open-label randomized multicenter phase II (window) trial in patients (pts) with head and neck squamous cell carcinoma (HNSCC). Treatment-naive HNSCC pts selected for primary curative study are randomized 3:3:3:1 in 4 neoadjuvant treatment groups: D 1500 mg on day 1 followed by O 600mg daily for 21-28 days (12 pts), cisplatin 60 mg/m2 on day 1 followed by O 75mg daily for 5 days (12 pts), monotherapy with O 600mg daily for 21-28 days (12 pts) and no treatment (5 pts). Preoperative therapy is discontinued 24 to 36 hours before surgery. Tumor biopsies, CT scans, PET and blood specimens are obtained at diagnosis and at surgery. Primary endpoint is the change in the tumor Ki-67 before and after treatment. Secondary endpoints are objective response rate according to RECIST 1.1 criteria, pathologic complete response rate and metabolic response rate assessed by FDG-PET/CT scan. Exploratory endpoints will include tumor and blood biomarkers. Translational correlates will be tested in tumor tissue, plasma and germline DNA and will include mutations in genes associated with DNA repair assessed by next generation sequencing and circulating tumor cells (CTCs) evaluated for DNA repair biomarkers and PD-L1. Trial is open to enrollment. Clinical trial information: NCT02882308.

Sign in / Sign up

Export Citation Format

Share Document